Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
Amount Raised
$102 Million
Round Type
Series C
CambridgeBiotechnologyTherapeuticsPharmaceuticalBiopharmaDescription
Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by Biotechnology Value Fund (BVF) and Redmile Group with participation from Wellington Management Company, Bain Capital Life Sciences, funds managed by Janus Henderson Investors and BlackRock, Rock Springs Capital and a large US-based, healthcare-focused fund. Existing investors also participated in the round.
Quick answer
Kymera Therapeutics raised $102 Million in a Series C round, dated March 12, 2020. Kymera Therapeutics is based in Cambridge, Massachusetts, United States.
- How much did Kymera Therapeutics raise?
- Kymera Therapeutics raised $102 Million in a Series C round on March 12, 2020.
- What does Kymera Therapeutics do?
- Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential..
- Where is Kymera Therapeutics based and how big is it?
- Kymera Therapeutics is based in Cambridge, Massachusetts, United States. Fundz records about 210 employees.
- Who are the decision-makers at Kymera Therapeutics?
- Fundz holds 2 contacts at Kymera Therapeutics, including the Talent Acquisition Partner. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Kymera Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- OnKure Therapeutics raised $3.2M (Seed) on April 15, 2020.
- iTeos Therapeutics, Inc. raised $125M on April 9, 2020.
- Nurix Therapeutics raised $120M on March 26, 2020.
- OnKure Therapeutics raised $1M (Seed) on March 6, 2020.
- VistaGen raised $2.8M (Seed) on January 31, 2020.
- Fate Therapeutics raised $50M on April 21, 2020.
Who to call at Kymera Therapeutics, and when
A new round usually means Kymera Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Kymera Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kymera Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kymera Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kymera Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Kymera Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.